Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22498
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Briasoulis, E. | en |
dc.contributor.author | Karavasilis, V. | en |
dc.contributor.author | Anastasopoulos, D. | en |
dc.contributor.author | Tzamakou, E. | en |
dc.contributor.author | Fountzilas, G. | en |
dc.contributor.author | Rammou, D. | en |
dc.contributor.author | Kostadima, V. | en |
dc.contributor.author | Pavlidis, N. | en |
dc.date.accessioned | 2015-11-24T19:24:34Z | - |
dc.date.available | 2015-11-24T19:24:34Z | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22498 | - |
dc.rights | Default Licence | - |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Agents, Phytogenic/*administration & dosage/adverse | en |
dc.subject | effects/therapeutic use | en |
dc.subject | Dose-Response Relationship, Drug | en |
dc.subject | Drug Administration Schedule | en |
dc.subject | Feasibility Studies | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasms/drug therapy | en |
dc.subject | Paclitaxel/administration & dosage/adverse effects/*analogs & | en |
dc.subject | derivatives/therapeutic use | en |
dc.subject | *Taxoids | en |
dc.title | Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration | en |
heal.type | journalArticle | - |
heal.type.en | Journal article | en |
heal.type.el | Άρθρο Περιοδικού | el |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10442193 | - |
heal.identifier.secondary | http://annonc.oxfordjournals.org/content/10/6/701.full.pdf | - |
heal.language | en | - |
heal.access | campus | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.publicationDate | 1999 | - |
heal.abstract | BACKGROUND: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly warranted. This is a dose-escalation study of weekly docetaxel particularly focused on the feasibility of long-term administration and characterisation of cumulative toxicity. PATIENTS AND METHODS: Twenty-six patients (11 female/15 male, median age 56, range 23-73) were treated over the range of 25-50 mg/m2/week. Dose-limiting toxicity for this schedule was defined as any grade > 2 antiproliferative toxic effect resulting in a > 2-week delay for re-administration of the drug, or any grade > 2 organ-specific toxicity. Patients were monitored clinically and electrophysiologically for neurotoxicity. No prolonged corticosteroid co-medication or prophylactic haematopoietic growth factors were given. RESULTS: A median/mean number of 8.5/8.7 consecutive weekly courses were given per patient. The maximum tolerated dose that prevented on-schedule administration of the drug was 50 mg/m2. The main cumulative toxicities were a mild fluid retention and dacryorrhea which became evident as the number of treatment courses increased. Grade 2 alopecia and fatigue were observed only at 45 mg/m2 and higher. Activity was seen at all of the dose levels studied. CONCLUSIONS: Long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m2/week with acceptable toxicity. Further clinical evaluation is justified at this schedule and 40 mg/m2/week of docetaxel is proposed for phase II studies as an active dose with minimal toxicity. | en |
heal.journalName | Ann Oncol | en |
heal.journalType | peer-reviewed | - |
heal.fullTextAvailability | TRUE | - |
Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Briasoulis-1999-Weekly docetaxel in.pdf | 500.23 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License